Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Mechanism of action of belantamab mafodotin

James Berenson • 12 Oct 2021
LLM 2021
Multiple Myeloma Antibodies Belantamab mafodotin

James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, outlines the mechanism of action of belantamab mafodotin, an anti-B cell maturation antigen (BCMA) antibody-drug conjugate indicated for relapsed/refractory multiple myeloma. Belantamab selectively binds to BCMA and the conjugated monomethyl auristatin F (MMAF) mediates myeloma cell death. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Disclosures

Speaker’s Bureau, Consulting, and Research Grant Support: BMS, Takeda Oncology, Karyopharm, Oncopeptides, and AMGEN
Speaker’s Bureau: Janssen and AMAG
Major Stockholder: ONCOtracker

More from James Berenson

1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
1:09
Medical writing bias in myeloma clinical research
James Berenson • 11 Dec 2023
2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023
1:08
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
James Berenson • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals